Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy
Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show.
Source: MedWire News - Oncology - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study | Tarceva | Toxicology